Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Antigenics brings in $26.1mm through private placement

Executive Summary

Antigenics (therapeutic vaccines for cancer and infectious diseases) raised $26.1mm through the private placement of 8.7mm common shares at $3 each (a 43% premium). Invus Public Equities led and was joined by Oracle Investment Management, other accredited investors, and Antigenics's CEO Dr. Garo Armen. Buyers also received ten-year warrants to purchase an additional 8.7mm common shares at $3 each, and unit warrants to purchase 8.7mm shares (with the same exercise terms) that would be triggered upon completion of a qualifying financial transaction within the next two years.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Liposomes
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies